The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
What are your research points that make you a lth, I've asked enough times. Go on ...I've given mine...with backup
Oneforrule. Thanks you made this a reason to invest here. Do you disagree? I mean you would only post here if you were positive right!?
Absolutely a total numpty.
PCS why are you here. What ticks your boxes? Jog on.when others wake up you are trying to manipulate here the sooner the better. Why are you here!!!
Bluenose what particular part of our iprs intrigue you? Why are you unhappy with me bringing up past RNSs re ipr and its journey? Stick to a worthwhile fact based ipr response that you back up with why you are here rather than having zero zilch Nada effective reason to dismiss my discussion points re the ipr here over years and their progress and patents?
You friends with jashar? Colleagues? Slyhuntress. Senator....
Where else are you expediting your profound knowledge of a company and advising you know better?
Just watch 737!
And so many miss the relevant points and digress without having an ounce of knowledge of the ipr here. I am perplexed some don't discuss the relevant ipr. I'm certain we are being played. I've got a further 20k to put in here when they stop playing with the spread and nonsensical posters disrupting.
Re my earlier post.
I cant post the link as its a pdf you open with drive.
Look up indigo.bluematrix.com 31st May 2018. A report from Hybridan. Re FLT3 going back to Sareum and looking at using nanoparticles for oral consumption. Of which we were/are privy to all findings. Ps nanoparticles are used pretty much everywhere if you research so not a conspiracy thing!
However it was noted that sareum would be focusing on 1801 and 1802.
I'm of the opinion that research garnered from flt3 has proved useful for 1801 and 1802 and the submarine patent.
I further believe that Hybridan will act mainly as corporate brokers re FLT3 due to experience of it and PH are here for 1801 1802.
The SRA 737 well we don't hold the cards on that but have a share but noteably AZ are mentioned some time ago re FLT3.
Coincidence with the recent Sierra Oncology link up?
Food for thought.
Regards Steadydanny
You remember the saying 'can't see the wood for the trees' ?
If you have 2 minutes look up the Hybridan report re FLT 3 and nanoparticles. Then look up nano particles in certain foods and other products. Then look up effects of nanoparticles and heart and lung conditions.
Then consider cytokine storms and cytotoxicity.
I can't copy the link bit hopefully someone can.
But the Chinese links with flt3 is of note!!!
I hope someone can post the link.
Not all of us see eye to eye but thank goodness this is a discussion board. As proven multiple times this year that any opinion is discussed appropriately if it has a backing point.
I wish you well and thank the informative posters of very relevant posts that cement sareums ipr and direction with a positive future imo.
Going to our local church in the morning for the Xmas service after a bit of smoked salmon and scrambled egg! I tend to be quieter when singing the hymns as I'm an awful singer. Despite sometimes being a bit brash here!
All in my prayers and there is a good crowd on here who with which I've seen genuine concerns if some have personal or family medical issues.
That helps with my faith in society. This is not just any company discussion board, its one where people are here for various reasons. It's not a pump and dump here. So much more if others read more deeply into the progress and destination.
If the reason I'm here is right well I'm hoping it will assist and aid alot of people with medical conditions that will hopefully be more treatable.
Best wishes to all
Steadydanny
PCS as per your post
SD with due respect you are not doing the research for others as you state if all you do is quote a RNS which is there for all all to read .
It appears potentially exciting times for SAR but some are believing that they are the toastmasters - let the facts be the news!
OK PCS let those who maybe have/don't have time to read the RNSs and bring a point of conversation that have gravitas re joining the corporate dots. So we should leave it to you to bring attention to noteable links re sareum.
Fckwt.
RNSs can be quite involved especially if you miss the chairman's points!
Not fussed who upvoted pcr but I hope he keeps you abreast of the RNSs.
Over to you PCR. You give your opinion that maybe day to day traders might like someone who actually gave a **** here.
GLA
Doolinater. Momentum re Sierra Oncology enterprises?
12 hours of trading before Xmas.
Bon soir HBD. This from September RNS. Getting tiresome doing the research for others . Not including you
SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.
We are in collaboration. We are a key part! Look at the datelines of 1801 and 1802 re 737. Tyk tok tyk tok
HBD where is the money? Delayed? Waiting for a news drop.
Is Citizens find that it has been used in humans? I think so.
Best regards Steadydanny
Just to continue. We are only as shareholders aware of what Sierra Oncology are undertaking with SRA737 as are or BODS.. I noted that 737 was getting more references in our RNSs since mid 2021.
And then Citizens find today!
I'm sure LTHs here remember 737 was written off and mothballed. But Sierras new employee conveniently said they would look at all pipelines with AZ. But now Citizens find.
My query to the posters who know their science. Citizen SOG and WIP et al.
How long would it have taken for the research re 737 and breast cancer to be undertaken to get these results?
So not sat on the shelf! Remember Sierras fireside chat!
Sincerely how long would these results require to be reported using 737?
What else are we holding back? And for how long?
And why?
Are we able to submit a Freedom of Information request?
Fantastic find Citizen. Oh my ! Pound to a penny the due diligence will be undertaken as to who has a stake in SRA737 by interested parties wanting a form of association and investment with said parties. Especially if their ipr catalogue is somewhat flawed and showing ongoing inconsistencies with initial predictions and later on facts.
Some big investors not happy with certain big pharmas! They are asking for proper researched ipr and Especially ones that have scientists on their boards. Which they are asking for. Tyk tok.
Not ramping but something is going to be revealed soon imo. And something very positive.
I doubt big pharmas close down for Xmas regarding worthwhile investment opportunities.
Very best regards to you Citizen and fellow Sareums.
I'm imagining Tim and the crew are looking at multiple options offered before them. I trust them to make the right one. They advise in their corporate objectives is to do the best for shareholders.
My biggest point of considered attention is do we have beef or turkey for Xmas day :-)
Or maybe we just have both!
Best wishes to our board and wow what a blinder they have played thus year backed up by HNWI SUBSCRIPTIONS and ongoing patent protections!!!!
Steadydanny
But from last RNS
As noted in its Final Results Statement of 25 October 2021, the Company is targeting the application for a Clinical Trials Authorisation for SDC-1801 in mid-2022, subject to successful progress. Clinical trial plans, including priority autoimmune indications and potential Covid-19 application, will also be developed in parallel. Preclinical development of SDC-1802 will be accelerated and is expected to complete in 2023, again subject to successful progress.
Just remember the new patents and personally I see this as an advertisement to the big pharmas. In or out!? Fully funded. So as per q and a 1802 would follow 1801 as very similar....2 iprs that will become game changing.
This will be huge.
Mafuta hi re my comment earlier I was wrong about breast cancer but cervical/ovarian possibly right it was Merck and GSK in September
Merck said it would end several remaining bintrafusp trials
including on lung cancer, breast cancer and bladder cancer. One
trial testing the drug against Cervical cancer would continue,
it added.
Family-controlled Merck KGaA and Merck & Co Inc, known as
MSD outside North America, share historic roots but have been
under separate ownership since World War One.
And this 18th October
Berenberg also saw stasis on returns from GSK's investments in research and development.
The analysts estimated that the company would generate a return from R&D investment of 6%, which was below its 8% cost of capital and in line with the previous two historical cohorts.
"Time is running out for management to deliver positive pipeline progress. Without Consumer Healthcare from mid-2022, "New GSK" will be increasingly exposed to its pharma R&D fortunes," they added.
The first extract re ww1 makes me twitch a bit. Given some research shared here some months ago re spanish flu and vaccines to tommies.
The second part needs an individual as you pointed out to expose r and d fortunes.
I'm expecting news here soon.
Citizen. Very interesting post. I'm racking my brain but there was a major pharma that stopped all of their ongoing research with a European collaborator about 4 months ago. All except if I'm not wrong but one program dealing with ovarian and breast cancer....I'm thinking it was GSK...probably wrong....Walmsley was getting some heat from major holders to add new iprs...and they are splitting GSK in two next year.
Just wondering if a collaboration might be a thought.
It's as if with the new shared subscription, and two of them (if involved in new one) could have /still can exercise warrants that they are individually able to do ...one below present sp and one under....but avoiding and still they are avoiding a TR1. But what if they came together with their shares and potential warrants if they hit greater than 10.25p for 5 plus days at a 1 for 1.125 option adding another £1.25m plus the others...
Gives a voting right I believe.
All very interesting. All just before January.
I see this as a very interesting period in Sareums history. Way above my pay grade.
The one thing I do have a better understanding of is the various iprs. That's why I'm invested.
All best Steadydanny
HBD it's why it's called a submarine patent. They release findings and then submerge it again. The process has tickled and if you go back about 4 months you will see my posts advising any pharma etc that partake in the released process and have anything akin to that research are required to pay royalties.
Looking good here.
Especially since they listed on 24th September;-)